RxDoctor Payments Data

Joni Couch

Optometrist · Muskogee, OKNPI 1073592002

Payments from drug & device makers

$547in general payments, 2019–2025

Across 17 payments — averaging $32.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$318
  • AbbVie$89
  • Sun Pharmaceutical Industries Inc.$75
  • Carl Zeiss Meditec AG$19
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$16
  • Rxsight Inc$15
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$52896%
  • Gifts$194%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$547 in reported general payments places this provider in the 45th percentile of 714 optometrist providers in Oklahoma.

See all optometrist providers in Oklahoma

Medicare billing

Part B allowed, 2024
$253,231
Medicare patients
1,058
Services billed
2,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost84$41,469
RestasisCyclosporine22$18,587
Prednisolone Acetate621$18,266
CombiganBrimonidine Tartrate/Timolol32$9,102
Ketorolac Tromethamine388$8,874
RhopressaNetarsudil Mesylate17$8,475
Ofloxacin385$4,500
Alphagan PBrimonidine Tartrate14$4,380
Brimonidine Tartrate257$3,834
Latanoprost277$3,009
Brinzolamide19$2,932
MoxifloxacinMoxifloxacin Hcl87$2,518
Travoprost21$2,271
Loteprednol Etabonate12$1,931
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$1,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$89$73,537152 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$16$1,93112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 714 optometrist providers in Oklahoma.

Other optometrist in Muskogee

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →